⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CORT News
Corcept Therapeutics Inc.
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym ®
businesswire.com
CORT
Lifshitz Law PLLC Announces Investigations of Kyndryl Holdings, Inc. (NYSE: KD), Corcept Therapeutics, Inc. (NASDAQ: CORT), NuScale Power Corporation (NYSE: SMR), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
accessnewswire.com
KD
CORT
SMR
RARE
Form 8-K
sec.gov
CORT
Form 8-K
sec.gov
CORT
Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
businesswire.com
CORT
Form 8-K
sec.gov
CORT
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
businesswire.com
CORT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT
globenewswire.com
CORT
Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
prnewswire.com
CORT
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
businesswire.com
CORT